[12] [11] While prescription GLP-1 agonists deliver pharmacologic doses that produce measurable clinical effects, the magnitude of GLP-1 elevation from probiotic supplementsif anyis substantially lower and clinically uncertain
Back in 2018, most of its earnings came from generics, with only a small share driven by innovation. Between 2025 and 2027, the company expects to bring dozens of major breakthroughs to market from GLP-1 therapies for obesity and diabetes to next-generation oncology treatments. Source: *Opinions are my own To view or add a comment, sign in Big Pharma News: Pfizer is set to acquire Metsera in a deal worth up to $4.9B Why it matters: $47.50/share upfront + $22.50/share tied to milestones Lead candidate MET-097i (GLP-1 therapy) showed 11.3% weight loss in 12 weeks Pipeline includes monthly amylin-based injections + oral obesity drugs Puts Pfizer head-to-head with Lilly & Novo Nordisk in the obesity race This move highlights the booming obesity drug market and pharmas growing appetite for metabolic innovation
In a Phase 2 clinical trial , adults with overweight or obesity taking the lowest dose (1 mg) lost about 8.7% of their body weight on average after 48 weeks
Skibicka KP
It will include integration with Eli Lillys self-pay pharmacy channel, called LillyDirect
If you experience significant nausea at 4mg, your provider might keep you at that dose longer before increasing
